Design and Synthesis of New Compounds Derived from Phenyl Hydrazine and Different Aldehydes as Anticancer Agents

Mo’men Salem^1*, Rezk Ayyad², Helmy Sakr², Ahmed Gaafer³

¹Medicinal Chemistry Department, Faculty of Pharmacy, Sinai University, Northern Sinai, Egypt.
²Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
³Medical Services Sector, Ministry of Intrior, Cairo, Egypt.

DOI: 10.4236/ijoc.2022.121003                

Abstract

In this work we synthesized new derivatives from Phenyl Hydrazine and series of different Aldehydes (derivatives of benzylidenes). The synthesized compounds contain different aromatic Aldehydes which attached by Benzene ring via Hydrazine moiety in glacial acetic acid. These derivatives were characterized by TLC, melting points, Infrared Red, Proton Nuclear Magnetic Resonance, Carbon Thirteen Nuclear Magnetic Resonance and Mass Spectroscopy. Finally, these synthesized derivatives were tested for antiproliferative activity against multiple normal and cancerous cell lines, HepG2 (Liver cancer) and MCF-7 (Breast cancer) cell lines were used for cytotoxic assay.

Keywords

Phenyl Hydrazine, Aromatic Aldehydes, Benzylidene Synthesis, Cytotoxic Assay, Anticancer, HepG2 and MCF-7

1. Introduction

Cancer is a public health menace. The disease is of a great concern to both developed and developing countries due to its high morbidity and mortality. In many countries, it has become second largest killer after cardiovascular disease [1]. In 2012, there were 14 million new cases and 8.2 million deaths [1]. Among men, lung cancer was the most predominant, while among women, it was breast cancer. It was reported that there were 24 million cancer cases annually and 14.6 million annual deaths by the end of 2015 [2]. These troubling figures compel policy makers and the researchers to combat this disease. Cancer is a collection of different life-threatening diseases characterized by uncontrolled growth of cells leading to invasion of surrounding tissue and often spreading to other parts of the body [3] [4]. Searching for new anticancer agents having heterocyclic nucleus continues worldwide at various laboratories [5] [6] [7]. It was reported that some aromatic compounds have demonstrated anticancer activities, but their mechanism of action is not established. For example, the anticancer activity of these compounds may be due to their intercalating properties or covalent binding abilities to DNA [8]. In addition, cell membrane interaction of these compounds is also proposed as their mechanism of actions [9]. In this work, organic compounds using Phenyl hydrazine and series of aromatic aldehydes are synthesized and tested as anticancer drugs, which have benzene ring attached to five or six membered rings (Benzimidazole) or (Phthalazine, Quinazoline, Quinoxalines). We aimed the synthesis of compounds formed of benzene ring attached by Hydrazine moiety which is two nitrogen atoms but not fused in the ring as Phthalazines, Quinazolines, Quinoxalines or Benzimidazoles [10] - [34]. These new compounds have two nitrogen atoms in side chain as a bridge between benzene ring and aromatic aldehydes.

2. Materials

2.1. Reagents

All solvents and reagents were obtained from commercial sources and were used without further purification except Glacial Acetic acid and Petroleum ether (PE). Phenyl Hydrazine was purchased from Sigma Aldrich (Cairo, Egypt). Series of Aromatic Aldehydes were acquired from Sigma Aldrich (Cairo, Egypt). Absolute Ethanol, Ehanol 95%, Glacial Acetic Acid, Ethyl Acetate, Petroleum Ether and Chloroform were purchased from Piochem (Cairo, Egypt). Distilled water was used for the experiments.

2.2. Instruments

Progress of chemical reactions was observed using TLC (Merck, silica gel plates 60 F254) and visualized using a UV-Vis spectrometer at 254 nm. Melting points were determined by Mel-Temp apparatus. NMR spectra were performed in Chloroform (7.26 ppm), with trimethyl silane as an internal standard, using Bruker Avance 500 spectrometer at ambient temperature, at drug discovery unit, Faculty of Pharmacy, Ain Shams University (ASU, Cairo, Egypt). All chemical shifts were expressed in parts per million (δ), and coupling constants (J) in Hz. FTIR spectra were recorded using KBr pellets on a model 883 double beam infrared spectrophotometer Bruker in 200 - 4000 cm⁻¹, at drug discovery unit, Faculty of Pharmacy, Ain Shams University (ASU, Cairo, Egypt). MS spectra were recorded using a Bruker Esquire 2000 by APC or ES ionization, at drug discovery unit, Faculty of Pharmacy, Ain Shams University (ASU, Cairo, Egypt).

2.3. Cell Culture: HepG2, MCF-7

Cell line was obtained from Nawah Scientific Inc. (Mokatam, Cairo, Egypt). Cells were maintained in DMEM media supplemented with 100 mg/mL of streptomycin, 100 units/mL of penicillin and 10% of heat-inactivated fetal bovine serum in humidified, 5% (v/v) CO₂ atmosphere at 37˚C [35] [36].

2.4. Cytotoxicity Assay: HepG2, MCF-7

Cell viability was assessed by SRB assay. Aliquots of 100 μL cell suspension (5 × 10³ cells) were in 96-well plates and incubated in complete media for 24 h. Cells were treated with another aliquot of 100 μL media containing drugs at various concentrations. After 72 h of drug exposure, cells were fixed by replacing media with 150 μL of 10% TCA and incubated at 4˚C for 1 h. The TCA solution was removed, and the cells were washed 5 times with distilled water. Aliquots of 70 μL SRB solution (0.4% w/v) were added and incubated in a dark place at room temperature for 10 min. Plates were washed 3 times with 1% acetic acid and allowed to air-dry overnight. Then, 150 μL of TRIS (10 mM) was added to dissolve protein-bound SRB stain; the absorbance was measured at 540 nm using a BMG LABTECH^®-FLUOstar Omega microplate reader (Ortenberg, Germany) [35] [36].

3. Chemistry and Scheme

3.1. Scheme

3.2. Procedure and Synthesis of Compounds 3-13

Equimolar mixture of Phenyl hydrazine and series of Aromatic Aldehydes were stirred together in refluxing glacial acetic acid (Figure 1). TLC was made by 2:1 Petroleum Ether: Ethyl Acetate system. Precipitate was obtained from organic layer then water was added and more precipitate was retrieved. Product was purified by crystallization in Absolute Ethanol.

Figure 1. General scheme for compounds (3-13): (i) Series of Aromatic Aldehydes, Refluxing Glacial Acetic Acid, 135˚C, 1 - 16 Hrs.

3.2.1. Compound 3: (E)-1-benzylidene-2-phenylhydrazine

Yield 70%. m.p = 154˚C - 156˚C. IR: 688.75, 747.51 cm⁻¹ (aromatic, bending), 880.40 cm⁻¹ (N-H, overtone), 1064.45 cm⁻¹ (C-N), 1518 cm⁻¹ (N-H, bending), 1590 cm⁻¹ (C=C, aromatic), 2450 cm⁻¹ (aromatic, overtone), 3090 cm⁻¹ (C-H, aromatic) and 3300 cm⁻¹ (N-H, stretching). ¹HNMR (400 MHz, CDCl₃): δ 6.90 - 7.50 ppm (m, aromatic protons), 7.65 ppm (s, -CH-) and 10.3 ppm (s, -NH-). ¹³CNMR (100 MHz, CDCl₃): δ C1 (144.5 ppm), C2 (117 ppm), C3 (114 ppm), C4 (137 ppm), C5 (114 ppm), C6 (117 ppm), C7 (146 ppm), C1 (147.5 ppm), C2 (115 ppm), C3 (130 ppm), C4 (125 ppm), C5 (130 ppm) and C6 (115 ppm).

3.2.2. Compound 4: (E)-1-(4-Methoxybenzylidene)-2-Phenylhydrazine

Yield 82.5%. m.p = 128˚C - 130˚C. ¹HNMR (400 MHz, CDCl₃): δ 3.86 ppm (s,-CH3-), 6.85 - 7.35 ppm (m, aromatic protons), 7.65 ppm (s,-CH-) and 9.9 ppm (s,-NH-). ¹³CNMR (100 MHz, CDCl₃): δ C1 (54.3 ppm), C2 (158.9 ppm), C3 (113.6 ppm), C4 (129.8 ppm), C5 (124.8 ppm), C6 (129.8), C7 (113.6 ppm), C8 (143.8 ppm), C1 (145.2 ppm), C2 (112.2 ppm), C3 (129.5 ppm), C4 (128.8 ppm), C5 (129.5 ppm) and C6 (112.2 ppm).

3.2.3. Compound 5: (E)-1-(2-Chlorobenzylidene)-2-Phenylhydrazine

Yield 73%. m.p = 129˚C - 131˚C. ¹HNMR (400 MHz, CDCl₃): δ 6.75 - 7.75 ppm (m, aromatic protons), 7.85 ppm (s, -CH-) and 10.5 ppm (s, -NH-). MS: m/z: 230.06 (100.0%), (M + 1) 231.05 (87.9%), (M + 2) 229.05 (12.1%).

3.2.4. Compound 6: 4-((2-Phenylhydrazono)methyl)phenol

Yield 86%. m.p = 178˚C - 181˚C. IR: 690.59, 743.83 cm⁻¹ (aromatic, bending), 884.73 cm⁻¹ (N-H, overtone), 1098.33 cm⁻¹ (C-N), 1504 cm⁻¹ (N-H, bending), 1596.49 cm⁻¹ (C=C, aromatic), 1700 cm⁻¹ (C=N), 3045 cm⁻¹ (C-H, aromatic), 3290 cm⁻¹ (N-H, stretching) and 2900 - 3625 cm⁻¹ (OH). ¹HNMR (400 MHz, CDCl₃): δ 6.85 - 7.55 ppm (m, aromatic protons), 7.7 ppm (s, -CH-), 7.85 ppm (s, -OH) and 9.88 ppm (s, -NH-). ¹³CNMR (100 MHz, CDCl₃): δ C1 (158.82 ppm), C2 (117.56 ppm), C3 (130.8 ppm), C4 (125.4 ppm), C5 (130.8 ppm), C6 (117.56), C7 (140.7 ppm), C1 (146.22 ppm), C2 (113.9 ppm), C3 (129.5 ppm), C4 (122.8 ppm), C5 (129.5 ppm) and C6 (113.9 ppm).

3.2.5. Compound 7: 4-((2-Phenylhydrazono)methyl) pyridine

Yield 73%. m.p = 179˚C - 181˚C. ¹HNMR (400 MHz, CDCl₃): δ 6.90-8.55 ppm (m, aromatic protons), 7.60 ppm (s, -CH-) and 8.15 (s, -NH-). ¹³CNMR (100 MHz, CDCl₃): δ C2 (149.98 ppm), C3 (120.13 ppm), C4 (143.47 ppm), C5 (120.13 ppm), C6 (149.98 ppm), C7 (142.84 ppm), C1 (133.55 ppm), C2 (113.09 ppm), C3 (129.42 ppm), C4 (121.13 ppm), C5 (129.42 ppm) and C6 (113.09 ppm).

3.2.6. Compound 8: (E)-1-(4-Nitrobenzylidene)-2-Phenylhydrazine

Yield 32.2%. m.p = 110˚C - 112˚C. ¹HNMR (400 MHz, CDCl₃): δ 6.80 - 7.40 ppm (m, aromatic protons), 7.55 ppm (s, -CH-) and 9.88 ppm (s, -NH-). ¹³CNMR (100 MHz, CDCl₃): δ C1 (147.18 ppm), C2 (119.06 ppm), C3 (119.84 ppm), C4 (144.93 ppm), C5 (119.84 ppm), C6 (119.06 ppm), C7 (137.29 ppm), C1 (145.85 ppm), C2 (111.66 ppm), C3 (129.28 ppm), C4 (112.71 ppm), C5 (129.28 ppm) and C6 (111.66 ppm).

3.2.7. Compound 9: (E)-1-(furan-2-Ylmethylene)-2-Phenylhydrazine

Yield 65%. m.p = 113 – 115˚C. IR: 692.95, 743.06 cm⁻¹ (aromatic, bending), 818.48 cm⁻¹ (N-H, overtone), 1153.57 cm⁻¹ (C-N), 1342.30 cm⁻¹ (C-O), 1602.35 cm⁻¹ (C=C, aromatic), 1604 cm⁻¹ (N-H, bending), 1655 cm⁻¹ (C=N), 2025 cm⁻¹ (C-H, aromatic overtone), 3090 cm⁻¹ (C-H, aromatic) and 3317.56 cm⁻¹ (N-H, stretching). ¹HNMR (400 MHz, CDCl₃): δ 6.85 - 7.55 ppm (m, aromatic protons), 7.60 ppm (s, -CH-) and 9.75 ppm (s, -NH-). ¹³CNMR (100 MHz, CDCl₃): δ C2 (144.36 ppm), C3 (112.89 ppm), C4 (120.46 ppm), C5 (150.55 ppm), C6 (142.72 ppm), C1 (143 ppm), C2 (112.96 ppm), C3 (129.31 ppm), C4 (127.83 ppm), C5 (129.31 ppm) and C6 (112.96 ppm).

3.2.8. Compound 10: (E)-1-Phenyl-2-((E)-3-Phenylallylidene) Hydrazine

Yield 80.5%. m.p = 150˚C - 152˚C. ¹HNMR (400 MHz, CDCl₃): δ 6.75 ppm (t,-CH-), 7.05 ppm (d,-CH-), 6.85 - 7.50 ppm (m, aromatic protons), 7.55 ppm (s,-CH-) and 9.75 ppm (s, -NH-). ¹³CNMR (100 MHz, CDCl₃): δ C1 (132.5 ppm), C2 (130 ppm), C3 (127 ppm), C4 (125 ppm), C5 (127 ppm), C6 (130 ppm), C7 (134 ppm), C8 (123 ppm), C9 (140 ppm), C1 (145 ppm), C2 (118 ppm), C3 (129 ppm), C4 (122 ppm), C5 (129 ppm) and C6 (118 ppm).

3.2.9. Compound 11: (E)-1-(4-Chlorobenzylidene)-2-Phenylhydrazine

Yield 80.1%. m.p = 119˚C - 121˚C. IR: 691.09, 746.28 cm⁻¹ (mono-sub.), 819.32 cm⁻¹ (para-di-sub.) (aromatic, bending), 882.19 cm⁻¹ (N-H, overtone), 1133.08 cm⁻¹ (C-N), 1518.02 cm⁻¹ (N-H, bending), 1598.38 cm⁻¹ (C=C, aromatic), 1620.02 cm⁻¹ (C=N), 2000 cm⁻¹ (C=C, aromatic), 3000 cm⁻¹ (C-H, aromatic) and 3310.61 cm⁻¹ (N-H, stretching). ¹HNMR (400 MHz, CDCl₃): δ 6.95-7.50 ppm (m, aromatic protons), 7.90 ppm (s,-CH-) and 10.10 ppm (s, -NH-). ¹³CNMR (100 MHz, CDCl₃): δ C1 (134.5 ppm), C2 (130.2 ppm), C3 (132.3 ppm), C4 (136.9 ppm), C5 (132.3 ppm), C6 (130.2 ppm), C7 (140.5 ppm), C1 (144.8 ppm), C2 (112 ppm), C3 (129.7 ppm), C4 (122.9 ppm), C5 (129 ppm) and C6 (112 ppm). MS: m/z: 230.06 (100.0%), (M + 1) 231.10 (63.7%), (M + 2) 229.05 (36.3%).

3.2.10. Compound 12: (E)-1-(4-Bromobenzylidene)-2-Phenylhydrazine

Yield 71%. m.p = 115˚C - 117˚C. ¹HNMR (400 MHz, CDCl₃): δ 7.0-7.60 ppm (m, aromatic protons), 7.98 ppm (s,-CH-) and 9.85 ppm (s, -NH-). ¹³CNMR (100 MHz, CDCl₃): δ C1 (129.3 ppm), C2 (133.3 ppm), C3 (131.5 ppm), C4 (136.7 ppm), C5 (131.5 ppm), C6 (133.3 ppm), C7 (142.8 ppm), C1 (145.6 ppm), C2 (113.8 ppm), C3 (128 ppm), C4 (121.4 ppm), C5 (128 ppm) and C6 (113.8 ppm). MS: m/z: 276 (100.0%), (M + 1) 278.95 (70%), (M + 2) 280.95 (30%).

3.2.11. Compound 13: 1,4-bis((2-Phenylhydrazono)methyl)benzene

Yield 62%. m.p = 220˚C - 222˚C. IR: 690.53, 743.71 cm⁻¹ (aromatic, bending), 885.30 cm⁻¹ (N-H, overtone), 1130.68 cm⁻¹ (C-N), 1522.08 cm⁻¹ (N-H, bending), 1588.48 cm⁻¹ (C=C, aromatic), 1600.36 cm⁻¹ (C=N), 1925.25 cm⁻¹ (C-H, aromatic overtone), 3075.25 cm⁻¹ (C-H, aromatic) and 3299.42 cm⁻¹ (N-H, stretching). ¹HNMR (400 MHz, CDCl₃): δ 6.95 - 7.90 ppm (m, aromatic protons), 7.75 ppm (s, -CH-), 10.03 ppm (s,-NH-). ¹³CNMR (100 MHz, CDCl₃): δ C1 (145 ppm), C2 (115 ppm), C3 (130 ppm), C4 (122 ppm), C5 (130 ppm), C6 (115 ppm), C7 (140 ppm), C8 (136 ppm), C9 (129 ppm), C10 (129 ppm), C11 (136 ppm), C12 (129 ppm), C11 (136 ppm), C12 (129 ppm), C13 (129 ppm), C14 (140 ppm), C15 (145 ppm), C16 (115 ppm), C17 (130 ppm), C18 (122 ppm), C19 (130 ppm) and C20 (115 ppm).

4. Results

4.1. Cytotoxicity Results of MCF-7

MCF-7 cell line was used to assay the antiproliferative activity of compounds (3-8), compound 8 was the most potent in this group with IC₅₀ value of 45.39 mm and compound 7 was the lowest in potency with IC₅₀ value of 100.09 mm (Figure 2). Microscopical examination of the tested compounds in the cell lines at concentration of 100 mm used to confirm the calculation of the IC₅₀ (Figure 3).

Figure 2. IC₅₀ Values of compounds 3-8 against MCF-7 Cell line [35] [36].

Figure 3. MCF-7 cell lines under microscopic examination of control and compounds (3 - 8) at 100 μm concentration [35] [36].

4.2. Cytotoxicity Results of HepG2

HepG2 cell line was used to assay the antiproliferative activity of compounds (9-13), compound 10 was the most potent in this group with IC₅₀ value of 127.69 mm and compound 13 was the lowest in potency with IC₅₀ value of 558.66 mm (Figure 4). Microscopical examination of the tested compounds in the cell lines at concentration of 100 mm used to confirm the calculation of the IC₅₀ (Figure 5).

Figure 4. IC₅₀ Values of compounds 9 - 13 against HepG2 Cell line [35] [36].

Figure 5. HepG2 cell lines under microscopic examination of control and compounds (9-13) at 100 μm concentration [35] [36].

4.3. Summary of the Cytotoxic assay Results of All Compounds

Figure 6. Summary of the cytotoxic assay results of all compounds against standard drugs [35] [36].

Figure 7. Summary of the cytotoxic assay results of all compounds against standard drugs [35] [36].

5. Conclusion

From the above findings, we concluded that all tested compounds have potential antiproliferative activity on both cell lines which were tested. For MCF-7 cell line, compound 8 was found to be the most potent compound in the group scoring 45.39 μm IC50, compound 7 was the lowest in potency scoring 100.09 μm IC50. For HepG2 cell line, compound 10 was found to be the most potent compound among the other compounds scoring 127.69 μm IC50 and compound 13 was the lowest in potency in this group (Figure 6, Figure 7).

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1]	Cancer: Factsheet No. 297 (2015, February). https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2015.html
[2]	International Agency for Cancer Research and World Health Organization (2014) World Cancer Factsheet 2014.
[3]	Bridges, A.J. (2001) Chemical Inhibitors of Protein Kinases. Chemical Reviews, 101, 2541-2572. https://doi.org/10.1021/cr000250y
[4]	Wang, J.D., Miller, K., Boschelli, D.H., Ye, F., Wu, B., Floyd, M.B., Powell, D.W., Wissner, A., Weber, J.M. and Boschelli, F. (2000) Inhibitors of Src Tyrosine Kinase: The Preparation and Structure-Activity Relationship of 4-Anilino-3-Cyanoquinolines and 4-Anilinoquinazolines. Bioorganic & Medicinal Chemistry Letters, 10, 2477-2480. https://doi.org/10.1016/S0960-894X(00)00493-5
[5]	Cai, S.X. (2007) Small Molecule Vascular Disrupting Agents: Potential New Drugs for Cancer Treatment. Recent Patents on Anti-Cancer Drug Discovery, 2, 79-101. https://doi.org/10.2174/157489207779561462
[6]	Shi, L.M., Fan, Y., Lee, J.K., Waltham, M., Andrews, D.T., Scherf, U., Paull, K.D. and Weinstein, J.N. (2000) Mining and Visualizing Large Anticancer Drug Discovery Databases. Journal of Chemical Information and Modeling, 40, 367-379. https://doi.org/10.1021/ci990087b
[7]	Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Wolff, V.A., Goodrich, M.G., Campbell, H., Mayo, J. and Boyd, M.J. (1991) Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. JNCI: Journal of the National Cancer Institute, 83, 757-766. https://doi.org/10.1093/jnci/83.11.757
[8]	Palmer, B.D., Rewcastle, G.W., Atwell, G.J., Baguley, B.C. and Denny, W.A. (1988) Potential Antitumor Agents. 54. Chromophore Requirements for in Vivo Antitumor Activity among the General Class of Linear Tricyclic Carboxamides. Journal of Medicinal Chemistry, 31, 707-712. https://doi.org/10.1021/jm00399a003
[9]	Denny, W.A., Rewcastle, G.W. and Baguley, B.C. (1990) Potential Antitumor Agents. 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-Carboxamides, a New Class of Minimal DNA-Intercalating Agents Which May Not Act via Topoisomerase II. Journal of Medicinal Chemistry, 33, 814-819. https://doi.org/10.1021/jm00164a054
[10]	Sakr, H.M., Ayyad R.R., Mahmoud, K., Mansour, A.M. and Ahmed, A.G. (2021) Design Synthesis of Analgesics and Anticancer of Some New Derivatives of Benzimidazole. International Journal of Organic Chemistry, 11, 144-169. https://doi.org/10.4236/ijoc.2021.113011
[11]	Khalifa, M.M., Sakr, H.M., Ibrahim, A., Mansour A.M. and Ayyad R.R. (2022) Design and Synthesis of New Benzylidene-Quinazolinone Hybrids as Potential Anti-Diabetic Agents: In Vitro α-Glucosidase Inhibition, and Docking Studies. Journal of Molecular Structure, 1250, Article ID: 131768. https://doi.org/10.1016/j.molstruc.2021.131768
[12]	El-Helby, A., Sakr, H.M., Ayyad R.R., Mahdi, H., Khalifa, M.M., Belal, A., et al. (2020) Design, Synthesis, Molecular Modeling, in Vivo Studies and Anticancer Activity Evaluation of New Phthalazine Derivatives as Potential DNA Intercalators and Topoisomerase II Inhibitors. Bioorganic Chemistry, 103, Article ID: 104233. https://doi.org/10.1016/j.bioorg.2020.104233
[13]	Ayyad, R.R. (2012) Synthesis and Biological Evaluation of Novel Iodophthalazinedione Derivatives as Anticonvulsant Agents. Al-Azhar Journal of Pharmaceutical Sciences, 45, 1-13. https://doi.org/10.21608/ajps.2012.7146
[14]	El-Dehna, W.M. Abou-Seri, S., El-Kerdawy, A., Ayyad, R.R., et al. (2016) Increasing the Binding Affinity of VEGFR-2 Inhibitors by Extending Their Hydrophobic Interaction with the Active Site: Design, Synthesis and Biological Evaluation of 1-Substituted-4-(4-Methoxybenzyl) Phthalazine Derivatives. European Journal of Medicinal Chemistry, 113, 50-62. https://doi.org/10.1016/j.ejmech.2016.02.029
[15]	El-Helby, A., Ayyad, R.R., Sakr, H.M., Abdul-Rahim, A.S., et al. (2017) Design, Synthesis, Molecular Modeling and Biological Evaluation of Novel 2,3-Dihydrophthalazine-1,4-Dione Derivatives as Potential Anticonvulsant Agents. Journal of Molecular Structure, 1130, 333-351. https://doi.org/10.1016/j.molstruc.2016.10.052
[16]	El-Helby, A., Ayyad, R.R., Sakr, H.M., El-Adl, K., Ali, M.M. and Khedr, F. (2017) Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors. Archiv der Pharmazie, 350, Article ID: 1700240. https://doi.org/10.1002/ardp.201700240
[17]	El-Helby, A., Ayyad, R.R., El-Adl, K. and El-Kady, H. (2019) Phthalazine-1,4-Dione Derivatives as Non-Competitive AMPA Receptor Antagonists: Design, Synthesis, Anticonvulsant Evaluation, ADMET Profile and Molecular Docking. Molecular Diversity, 23, 283-298. https://doi.org/10.1007/s11030-018-9871-y
[18]	Eissa, I.H., Metwally, A.M., Belal, A. and Mehany, A.B. (2019) Discovery and Antiproliferative Evaluation of New Quinoxalines as Potential DNA Intercalators and Topoisomerase II Inhibitors. Archiv der Pharmazie, 352, Article ID: 1900123. https://doi.org/10.1002/ardp.201900123
[19]	Kamal, I.M., Abdul-Rahman, A.A., Ayyad R.R. and El-Adl, K. (2013) Design and Synthesis of Some Novel 2-(3-Methyl-2-Oxoquinoxalin-1(2H)-yl)-N-(4-(substituted)-Phenyl) Acetamide Derivatives for Biological Evaluation as Anticonvulsant Agents. Bulletin of Faculty of Pharmacy, Cairo University, 51, 101-111. https://doi.org/10.1016/j.bfopcu.2012.11.003
[20]	El-Helby, A., Ayyad, R.R. and Zayed, M.F. (2011) Synthesis and Biological Evaluation of Some Novel Quinoxaline Derivatives as Anticonvulsant Agents. Arzneimittelforschung, 61, 379-381. https://doi.org/10.1055/s-0031-1296214
[21]	El-Helby, A., Ayyad R.R., El-Adl, K. and Elwan, A. (2017) Quinoxalin-2(1H)-One Derived AMPA-Receptor Antagonists: Design, Synthesis, Molecular Docking and Anticonvulsant Activity. Medicinal Chemistry Research, 26, 2967-2984. https://doi.org/10.1007/s00044-017-1996-5
[22]	El-Helby, A., Ayyad R.R., Zayed, M.F. and Abou-El-Kheer, H.S. (2019) Design, Synthesis, in Silico ADMET Profile and GABA-A Docking of Novel Phthalazines as Potent Anticonvulsants. Archiv Der Pharmazie, 352, Article ID: 1800387. https://doi.org/10.1002/ardp.201800387
[23]	El-Helby, A., Ayyad, R.R., Sakr, H.M. and El-Adl, K. (2018) Design, Synthesis, in Vitro Anti-Cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo [3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. Anti-Cancer Agents in Medicinal Chemistry, 18, 1184-1196. https://doi.org/10.2174/1871520618666180412123833
[24]	Ekhlass, M.N., Abdul Razek F.M., Ayyad R.R. and El-Farargy, A.F. (2016) Synthesis and Some Reactions of 1-Aryl-4-Acetyl-5-Methyl-1, 2, Triazole Derivatives with Anticonvulsant Activity. Mini-Reviews in Medicinal Chemistry, 16, 926-936.
[25]	Ayyad, R.R. (2014) Synthesis and Anticonvulsant Activity of 6-Iodo Phthalazinedione Derivatives. Al-Azhar Journal of Pharmaceutical Sciences, 50, 43-54. https://doi.org/10.21608/ajps.2016.6930
[26]	El-Helby, A. Ibrahim, M.K., Abdul Rahman, A.A., Ayyad, R.R., Menshawy, M.A. and El-Adl, K. (2009) Synthesis, Molecular Modeling and Anticonvulsant Activity of Benzoxazole Derivatives. Al-Azhar Journal of Pharmaceutical Sciences, 40, 252-270.
[27]	Ayyad, R.R., Sakar, H.M. and El-Gammal, K. (2016) Synthesis, Modeling and Anticonvulsant Activity of Some Phthalazinedione. American Journal of Organic Chemistry, 6, 29-38.
[28]	Ayyad, R.R. (2008) Synthesis and Anticonvulsant Activity of Tetrabromophthalazinedione. Al-Azhar Journal of Pharmaceutical Sciences, 50, 33-45.
[29]	El-Helby, A., Ibrahim, M.K., Amin, M.A. and Ayyad, R.R. (2020) Synthesis and Anticonvulsant Activity of Phthalazindione Derivatives. Al-Azhar Journal of Pharmaceutical Sciences, 28, 22-35.
[30]	Ibrahim, M.K., Abdel-Rahman A.A., Ayyad, R.R., El-Adl, K., El-Sherbeny, F. and Rashed, M. (2010) Design and Synthesis of Some Novel N-Phthalimide Derivatives with Potential Anticonvulsant Activity. Al-Azhar Journal of Pharmaceutical Sciences, 42, 305-322.
[31]	Alaa, A.M., Abou-Zeid, L.A., El-Tahir, K.H., Ayyad, R.R., Magda, A.A. and El-Azab, A.S. (2016) Synthesis, Anti-Inflammatory, Analgesic, COX-1/2 Inhibitory Activities and Molecular Docking Studies of Substituted 2-Mercapto-4(3H)-Quinazolinones. European Journal of Medicinal Chemistry, 121, 410-421. https://doi.org/10.1016/j.ejmech.2016.05.066
[32]	Menshawy, M.A., Ayyad, R.R., Shawer, T.Z. and Alaa, A.M. (2016) Synthesis and Antitumor Evaluation of Trimethoxyanilides Based on 4(3H)-Quinazolinone Scaffolds. European Journal of Medicinal Chemistry, 112, 106-113. https://doi.org/10.1016/j.ejmech.2016.02.002
[33]	Hall, J.H., Hall, E.S. and Wong, O.T. (1992) Cumulated Index Medicus. Anti-Cancer Drug, 3, 55-62. https://doi.org/10.1097/00001813-199202000-00010
[34]	Soje-Echaque, E. and Lim, R.K. (1962) Inflammation and Anti-Inflammatories. Spectrum, New York, USA. Journal of Pharmacology and Experimental Therapeutics, 49, 138-224.
[35]	Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J. and Vistica, D. (1990) New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening. JNCI: Journal of the National Cancer Institute, 82, 1107-1112. https://doi.org/10.1093/jnci/82.13.1107
[36]	Allam, R.M., Al-Abd, A.M., Khedr, A. and Sharaf, O.A. (2018) Fingolimod Interrupts the Cross Talk between Estrogen Metabolism and Sphingolipid Metabolism within Prostate Cancer Cells. Toxicology Letters, 291, 77-85. https://doi.org/10.1016/j.toxlet.2018.04.008